Evidence map›Paper›PMID 39429811›Full record

ReviewEClinicalMedicine2024

Promoting diversity in clinical trials: insights from planning the ALUMNI AD study in historically underrepresented US populations with early symptomatic Alzheimer's disease.

Alexandria Wise-Brown, Sharon A Brangman, J Neil Henderson, Monica Willis-Parker, Stephanie Monroe, Jacobo E Mintzer, Michael Grundman, Janice Smith, Rachelle S Doody, Helen Lin and 4 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in EClinicalMedicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Trial
  2. Observational
  3. Review
  4. Review
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Alexandria Wise-BrownGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.
Sharon A BrangmanDepartment of Geriatrics, SUNY Upstate Medical University, Syracuse, NY, USA.
J Neil HendersonDepartment of Family Medicine and BioBehavioral Health, University of Minnesota, Duluth, MN, USA.
Monica Willis-ParkerGoizueta Alzheimer's Disease Research Center, Emory University School of Medicine; Minority Engagement Core, Atlanta, GA, USA.
Stephanie MonroeCenter for Brain Health Equity, UsAgainstAlzheimer's, Washington, DC, USA.
Jacobo E MintzerDepartment of Health Studies, Medical University of South Carolina, Charleston, SC, USA.
Michael GrundmanGlobal R&D Partners, LLC, San Diego, CA, USA.
Janice SmithRoche Products Ltd, Welwyn Garden City, United Kingdom.
Rachelle S DoodyGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.
Helen LinGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.
Beverly AssmanGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.
Gregory A RipponGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.
Rozanno GonzalesGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.
Sheila Seleri AssunçãoGenentech, Inc., a member of the Roche Group, US Medical Affairs, South San Francisco, CA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Clinical trial participation across disease areas, including Alzheimer's disease (AD), has been biased towards White participants of European ancestry. To support clinical decision-making across diverse populations, we must recognize and address barriers to trial participation. To inform the design of ALUMNI AD, a trial focused on historically underrepresented AD populations, we held advice-seeking fora with key stakeholders to understand barriers and identify potential solutions to maximize trial participation of underrepresented racial and ethnic groups in the US. Strategies identified from this process include: obtaining and implementing recommendations from community stakeholders; establishing a simple and inclusive prescreening and screening process; supporting participants and care partners; identifying and activating community-centric clinical sites; and demonstrating community commitment. While ALUMNI AD did not commence, we hope that our insights could be incorporated into future studies to improve diversity, equity, and inclusion in AD clinical research. Funding: This study was sponsored by Genentech, Inc.

Indexed as

Alzheimer's diseaseClinical trial protocolDiversity, Equity, InclusionSocial determinants of healthUnderrepresentation

Identifiers

PMID39429811
PMCPMC11490654

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.